
ASX News
Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product
Melbourne (Australia) – 2nd December 2020. Telix has been granted HREC approval and received CTN clearance by the TGA to commence Phase I study of the Company’s next generation prostate cancer therapy product TLX592, in patients with advanced prostate cancer.
Telix Pharmaceuticals Limited is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Therapeutic Goods Administration (TGA) to commence its first-in-human Phase I study of the Company’s next generation prostate cancer therapy product TLX592, in patients with advanced prostate cancer.
TLX592 has been developed using Telix’s proprietary RADmAb® engineered antibody technology. Like the Company’s existing TLX591 antibody development program, TLX592 targets prostate specific membrane antigen (PSMA) – a target that is almost ubiquitously expressed by prostate cancer cells. TLX592 has been engineered to clear far more rapidly from a patient’s circulation, making it suitable for use as a targeting agent for 225Ac (actinium-225). Actinium is a potent therapeutic alpha (α) emitting radionuclide and treatment with α-emitting radionuclides is commonly referred to “Targeted Alpha Therapy” or “TAT”.
The Phase I ‘CUPID’ study is a single centre, open-label trial that will evaluate the safety and tolerability, pharmacokinetics, biodistribution and radiation dosimetry of TLX592 in patients with advanced prostate cancer.
Telix CEO, Dr Chris Behrenbruch said: “We are delighted to have been granted approval to commence the Phase I CUPID study for TLX592. Telix’s proprietary RADmAb® technology fundamentally underpins our ability to develop new TAT treatments for patients with metastatic cancer. In the case of TLX592, the clinical objective is to treat patients with prostate cancer that have a low disease burden for which alpha therapy is ideally suited, as well as potentially treating patients that no longer respond to conventional lutetium PSMA therapy (177Lu-PSMA). Telix has one of the biggest TAT pipelines in the industry and we are pleased to see our R&D efforts heading into the clinic.”
To read the full ASX release, please click here.
For our related investor briefing, please click here.
More Articles
ASX News
First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...
Corporate Spotlight
Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific
22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific
Corporate Spotlight
ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...
ASX News
Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product
Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...
ASX News
Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance
Melbourne (Australia) – 16th December 2020. Telix Pharmaceuticals announces collaboration with Mauna Kea Technologies to develop advanced image-guided surgical technologies in the field...
ASX News
Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging
Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...
ASX News
Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data
Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...
ASX News
Telix Granted TGA Priority Review for Prostate Cancer Imaging
Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...
ASX News
Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging
Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...
ASX News
Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product
Melbourne (Australia) – 2nd December 2020. Telix has been granted HREC approval and received CTN clearance by the TGA to...
ASX News
Investor Briefing – TheraPharm GmbH Acquisition
Melbourne (Australia) – 1st December 2020. Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH Acquisition
ASX News
Telix Pharmaceuticals Limited Acquires TheraPharm GmbH
Melbourne (Australia) and Baar (Switzerland) – 30th November 2020. Telix announces it has entered into an agreement with Scintec Diagnostics...
ASX News
Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 24th November 2020. Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit...